Disclosure statement
The authors declare no conflict of interest.
Additional information
Notes on contributors
Gianluca Dell’Orso
Gianluca Dell'Orso is a MD, Resident in Pediatrics at University of Genoa, Italy. He carries out his clinical activity in Department of Hematology-Oncology, specifically in Hematopoietic Stem Cell Unit in Istituto Giannina Gaslini, Genoa. He has a special research interest in Stem Cell Transplantation, Hematology and Immunology.
Maura Faraci
Maura Faraci is a MD, Director of HSCT Program at Istituto G Gaslini. Member of Italian and European transplant association. She has a special research interest in Graft versus host disease, acute and chronic toxicity after HSCT.
Stefano Giardino
Stefano Giardino is a MD, Specialized in Pediatrics. He carries out his clinical activity in Hematopoietic Stem Cell Transplantation Unit at Istituto Giannina Gaslini in Genoa, Italy. His main research interests are in the field of hematology, particularly about bone marrow failure syndromes, and stem cell transplantation from alternative donor.
Marcello Mariani
Marcello Mariani is MD, specialized in Pediatrics, PhD student in Pediatric Sciences. He has a special research interest in pediatric infectious diseases, antibiotic therapy, PK / PD, antibiotic dosing, PICU infections.
Alessio Mesini
Alessio Mesini is a MD, PhD specialized in Infectious Diseases. He carries out his clinical activity in Infectious Diseases Unit in Istituto Giannina Gaslini. He has a special research interest in bacterial and fungal infection in critical pediatric patient.
Elio Castagnola
Elio Castagnola is MD, PhD, Chief of Infectious Diseases Unit at Istituto Giannina Gaslini, Genoa, Italy. He has a special research interest in pediatric infectious diseases, in particular in immunocompromised patients, antibiotic therapy, PK / PD, antibiotic dosing, PICU infections.